Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-cd9895bd7-jkksz Total loading time: 0 Render date: 2025-01-01T17:29:51.907Z Has data issue: false hasContentIssue false

4 - Neuroreceptor imaging of schizophrenia

from Section I - Schizophrenia

Published online by Cambridge University Press:  10 January 2011

By
Dean F. Wong ,
James Robert Brašić  and
Nicola Cascella
Edited by
Martha E. Shenton  and
Bruce I. Turetsky
Dean F. Wong
Affiliation:
The Russel H. Morgan Department of Radiology and Radiological Science The Johns Hopkins University School of Medicine Baltimore, MD, USA
James Robert Brašić
Affiliation:
The Russell H. Morgan Department of Radiology and Radiological Science The Johns Hopkins University School of Medicine Baltimore, MD, USA
Nicola Cascella
Affiliation:
Department of Psychiatry and Behavioral Sciences The Johns Hopkins University School of Medicine Baltimore, MD, USA
Martha E. Shenton
Affiliation:
VA Boston Healthcare System and Brigham and Women's Hospital, Harvard Medical School
Bruce I. Turetsky
Affiliation:
University of Pennsylvania
Get access

Summary

Introduction

Since the development of neuroreceptor positron emission tomography (PET) imaging in the 1980s, the application of this novel in-vivo technology has revolutionized the study of schizophrenia for pathophysiology and drug development. This now-coined “molecular imaging” in schizophrenia has a historical root in the very basis of in-vivo neuroreceptor imaging with PET and single-photon emission computed tomography (SPECT). Indeed, the first successful imaging study in 1983 in living human brain was with a radiolabeled antipsychotic, spiperone (Spiroperidol), labeled with [11C]-methyl iodine (Wagner et al.,1983), and later with [18F]. This was followed with the isotopic labeling of [11C]-raclopride (i.e. no change in the chemical structure or pharmacology), also an antipsychotic and D2/D3 dopamine (DA) antagonist. Both unlabeled spiperone and raclopride have been studied for their potential therapeutic value for schizophrenia in clinical trials. Although neither of these antipsychotics was used clinically, their radiolabeled PET analogs led the way for studying D2-like dopamine receptors, and opened up the entire field of studying neuroreceptors as essentially a new subspecialty of neuroimaging with tremendous application in neuropsychiatry. These two radiotracers were quickly shown to be displaceable by unlabeled marketed antipsychotics such as haloperidol (Haldol), which led ultimately to dopamine D2/D3 occupancy studies (see below), and guidance of therapeutic drug dose levels now being visualized in human brain. Most importantly, they illustrate the merging of basic psychopharmacology, CNS nuclear medicine methodology, and in-vivo neuropsychiatric applications.

Keywords

anti-psychotic medicationdopamine imagingglutamate system imagingsingle-photon emission computed tomographyserotonin imagingschizophrenianeuroreceptor imagingpositron emission tomography
Type
Chapter
Information
Understanding Neuropsychiatric Disorders
Insights from Neuroimaging
 , pp. 78 - 87
Publisher: Cambridge University Press
Print publication year: 2010

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Abi-Dargham, A, Kegeles, L S, Zea-Ponce, Y, et al. 2004. Striatal amphetamine-induced dopamine release in patients with schizotypal personality disorder studied with single photon emission computed tomography and [123I]iodobenzamide. Biol Psychiatry 55, 1001–06.Google Scholar
Abi-Dargham, A, Rodenhiser, J, Printz, D, et al. 2000. Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc Natl Acad Sci U S A 97, 8104–09.Google Scholar
Adams, B W, Bradberry, C W and Moghaddam, B. 2002. NMDA antagonist effects on striatal dopamine release: microdialysis studies in awake monkeys. Synapse 43, 12–8.Google Scholar
Breier, A, Su, T P, Saunders, R, et al. 1997. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc Natl Acad Sci U S A 94, 2569–74.Google Scholar
Buchsbaum, M S, Christian, B T, Lehrer, D S, et al. 2006. D2/D3 dopamine receptor binding with [F-18]fallypride in thalamus and cortex of patients with schizophrenia. Schizophr Res 85, 232–44.Google Scholar
Carlsson, A. 1999. Birth of neuropsychopharmacology – impact on brain research. Brain Res Bull 50, 363.Google Scholar
Carlsson, A, Waters, N and and Carlsson, M L. 1999. Neurotransmitter interactions in schizophrenia – therapeutic implications. Biol Psychiatry 46, 1388–95.Google Scholar
Carson, R E, Breier, A, Bartolomeis, A, et al. 1997. Quantification of amphetamine-induced changes in [11C]raclopride binding with continuous infusion. J Cerebr Blood Flow and Metab 17, 437–47.Google Scholar
Davidson, L L and Heinrichs, R W. 2003. Quantification of frontal and temporal lobe brain-imaging findings in schizophrenia: a meta-analysis. Psychiatry Res 122, 69–87.Google Scholar
Erritzoe, D, Rasmussen, H, Kristiansen, K, et al. 2006. Serotonin 2A binding in neuroleptics-naïve schizophrenic patients and healthy controls using PET and [18-F]altanserin. NeuroImage 31, T44–186 [Abstract].Google Scholar
Erritzoe, D, Rasmussen, H, Kristiansen, K T, et al. 2008. Cortical and subcortical 5-HT2A receptor binding in neuroleptic-naive first-episode schizophrenic patients. Neuropsychopharmacology 33, 2435–41.Google Scholar
Farde, L, Hall, H, Ehrin, E and Sedvall, G 1986. Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET. Science 231, 258–61.Google Scholar
Farde, L, Wiesel, F A, Halldin, C and Sedvall, G. 1988. Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry 45, 71–6.Google Scholar
Farde, L, Wiesel, F A, Stone-Elander, S, et al. 1990. D2 dopamine receptors in neuroleptic-naive schizophrenic patients. A positron emission tomography study with [11C]raclopride. Arch Gen Psychiatry 47, 213–9.Google Scholar
Frankle, W G, Narendran, R, Huang, Y, et al. 2005. Serotonin transporter availability in patients with schizophrenia: a positron emission tomography imaging study with [11C]DASB. Biol Psychiatry 57, 1510–6.Google Scholar
Grace, A A 1991. Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia. Neuroscience 41, 1–24.Google Scholar
Gründer, G, Carlsson, A and Wong, D F. 2003. Mechanism of new antipsychotic medications: occupancy is not just antagonism. Arch Gen Psychiatry 60, 974–7.Google Scholar
Gründer, G, Fellows, C, Janouschek, H, et al. 2008. Brain and plasma pharmacokinetics of aripiprazole in patients with schizophrenia: An [18F]fallypride PET study. Am J Psychiatry 165, 988–95.Google Scholar
Hurlemann, R, Boy, C, Meyer, P T, et al. 2005. Decreased prefrontal 5-HT2A receptor binding in subjects at enhanced risk for schizophrenia. Anat Embryol (Berl) 210, 519–23.Google Scholar
Innis, R B, Cunningham, V J, Delforge, J, et al. 2007. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab 27, 1533–9.Google Scholar
Joyce, J N, Shane, A, Lexow, N, Winokur, A, Casanova, M F and Kleinman, J E 1993. Serotonin uptake sites and serotonin receptors are altered in the limbic system of schizophrenics. Neuropsychopharmacology 8, 315–36.Google Scholar
Krystal, J H, Abi-Saab, W, Perry, E, et al. 2005. Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects. Psychopharmacology (Berl) 179, 303–9.Google Scholar
Laruelle, M. 1998. Imaging dopamine transmission in schizophrenia. A review and meta-analysis. Q J Nucl Med 42, 211–21.Google Scholar
Laruelle, M, Abi-Dargham, A, Casanova, M F, Toti, R, Weinberger, D R and Kleinman, J E. 1993. Selective abnormalities of prefrontal serotonergic receptors in schizophrenia: a postmortem study. Arch Gen Psychiatry 50, 810–8.Google Scholar
Laruelle, M, Abi-Dargham, A, Dyck, C H, Gil, R and D'Souza, C D. 1996. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci U S A 93, 9235–40.Google Scholar
Laruelle, M, Abi-Dargham, A, Dyck, C, et al. 2000. Dopamine and serotonin transporters in patients with schizophrenia: an imaging study with [(123)I]beta-CIT. Biol Psychiatry 47, 371–9.Google Scholar
Martinez, D, Gelernter, J, Abi-Dargham, A, et al. 2001. The variable number of tandem repeats polymorphism of the dopamine transporter gene is not associated with significant change in dopamine transporter phenotype in humans. Neuropsychopharmacology 24, 553–60.Google Scholar
Matusch, A, Hurlemann, R, Rota Kops, E, et al. 2007. Acute S-ketamine application does not alter cerebral [18F]altanserin binding: a pilot PET study in humans. J Neural Transm 114, 1433–42.Google Scholar
Mukherjee, J, Christian, B T, Dunigan, K A, et al. 2002. Brain imaging of 18F-fallypride in normal volunteers: blood analysis, distribution, test-retest studies and preliminary assessment of sensitivity to aging effects on dopamine D2/D3 receptors. Synapse, 46, 170–88.Google Scholar
Mukherjee, J, Christian, B T, Narayanan, T K, Shi, B and Collins, D 2005. Measurement of d-amphetamine-induced effects on the binding of dopamine D2/D3 receptor radioligand, 18F-fallypride in extrastriatal brain regions in non human primates using PET. Brain Res 1032, 77–84.Google Scholar
Mukherjee, J, Christain, B T, Narayanan, T K, Shi, B and Mantil, J. 2001. Evaluation of dopamine D2 receptor occupancy by clozapine, risperidone and haloperidol in vivo in the rodent and nonhuman primate brain using 18F-fallypride. Neuropsychopharmacology, 25, 476–88.Google Scholar
Mukherjee, J, Shi, B, Christian, B T, Chattopadhyay, S, and Narayanan, T K. 2004. 11C-fallypride: radiosynthesis and preliminary evaluation of a novel dopamine D2/D3 receptor PET radiotracer in non-human primate brain. Bioorg Med Chem 12, 95–102.Google Scholar
Munro, C A, McCaul, M E, Oswald, L M, et al. 2006a. Striatal dopamine release and family history of alcoholism. Alcohol Clin Exp Res 30, 1143–51.Google Scholar
Munro, C A, McCaul, M E, Wong, D F, et al. 2006b. Sex differences in striatal dopamine release in healthy adults. Biol Psychiatry 59, 966–74.Google Scholar
Nozaki, S, Kato, M, Takano, H, et al. 2009. Regional dopamine synthesis in patients with schizophrenia using L-[beta-11C]DOPA PET. Schizophr Res 108, 78–84.Google Scholar
Nyberg, S, Olsson, H, Nilsson, U, Maehlum, E, Halldin, C and and Farde, L 2002. Low striatal and extra-striatal D2 receptor occupancy during treatment with the atypical antipsychotic sertindole. Psychopharmacology (Berl) 162, 37–41.Google Scholar
Oswald, L M, Wong, D F, McCaul, M, et al. 2005. Relationships among ventral striatal dopamine release, cortisol secretion, and subjective responses to amphetamine. Neuropsychopharmacology 30, 821–32.Google Scholar
Rasmussen, H, Erritzoe, D, Andersen, R, et al. 2010. Decreased frontal serotonin 2A receptor binding in antipsychotic-naïve patients with first-episode schizophrenia. Arch Gen Psychiatry 67, 9–16.Google Scholar
Reith, J, Benkelfat, C, Sherwin, A, et al. 1994. Elevated dopa decarboxylase activity in living brain of patients with psychosis. Proc Natl Acad Sci U S A 91, 11 651–4.Google Scholar
Singer, H S, Szymanski, S, Guiliano, J, et al. 2002. Elevated intrasynaptic dopamine release in Tourette's syndrome measured by PET. Am J Psychiatry 159, 1329–36.Google Scholar
Talvik-Lotfi, M, Nyberg, S, Nordström, A L, et al. 2000. High 5HT2A receptor occupancy in M100907-treated schizophrenic patients. Psychopharmacology (Berl) 148, 400–03.Google Scholar
Wagner, H N, Jr, Burns, H D, Dannals, R F, et al. 1983. Imaging dopamine receptors in the human brain by positron tomography. Science 221, 1264–6.Google Scholar
Wong, D F. 2002a. In vivo imaging of D2 dopamine receptors in schizophrenia: the ups and downs of neuroimaging research. Arch Gen Psychiatry 59, 31–4.Google Scholar
Wong, D F. 2002b. [Erratum] In vivo imaging of D2 dopamine receptors in schizophrenia: the ups and downs of neuroimaging research. Arch Gen Psychiatry 59, 440.Google Scholar
Wong, D F, Potter, W Z and Brašić, J R 2002. Proof of concept: functional models for drug development in humans. In Davis, K L, Charney, D, Coyle, J T and Nemeroff, C (Eds) Neuropsychopharmacology: The Fifth Generation of Progress. Baltimore, MD: Lippincott Williams and Wilkins, pp. 457–73.
Wong, D F and Brašić, J R 2005. Progress in the neuropsychiatry of schizophrenia. Psychiatric Times 22(3), 57–60.Google Scholar
Wong, D F, Gjedde, A, Wagner, H N, et al. 1986. Quantification of neuroreceptors in the living human brain. II. inhibition studies of receptor density and affinity. J Cerebr Blood Flow Metab 6, 147–53.Google Scholar
Wong, D F, Kuwabara, H, Schretlen, D J, et al. 2006. Increased occupancy of dopamine receptors in human striatum during cue-elicited cocaine craving. Neuropsychopharmacology 31, 2716–27. Erratum in: Neuropsychopharmacology 2007; 32, 256.Google Scholar
Wong, D F, Brašić, J R, Singer, H S, et al. 2008. Mechanisms of dopaminergic and serotonergic neurotransmission in Tourette Syndrome: clues from an in vivo neurochemistry study with PET. Neuropsychopharmacology 33, 1239–51.Google Scholar
Wong, D F, Maini, A, Rousset, O G and Brašić, J R 2003. Positron emission tomography: a tool for identifying the effects of alcohol dependence on the brain. Alcohol Res Health 27, 161–73.Google Scholar
Wong, D F, Tauscher, J and Gründer, G 2009. The role of imaging in proof of concept for CNS drug discovery and development. Neuropsychopharmacology, 34, 187–203.Google Scholar
Wong, D F, Wagner, H N Jr, Dannals, R F, et al. 1984. Effects of age on dopamine and serotonin receptors measured by positron tomography in the living human brain. Science 226, 1393–6. Google Scholar
Yasuno, F, Suhara, T, Okubo, Y, et al. 2004. Low dopamine d(2) receptor binding in subregions of the thalamus in schizophrenia. Am J Psychiatry 161, 1016–22. Google Scholar
Yokoi, F, Gründer, G, Biziere, K, et al. 2002. Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride. Neuropsychopharmacology 27, 248–59.Google Scholar
Zanardi, R, Artigas, F, Moresco, R, et al. 2001. Increased 5-hydroxytryptamine-2 receptor binding in the frontal cortex of depressed patients responding to paroxetine treatment: a positron emission tomography scan study. J Clin Psychopharmacol 21, 53–8.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

  • Neuroreceptor imaging of schizophrenia
    • By Dean F. Wong, The Russel H. Morgan Department of Radiology and Radiological Science The Johns Hopkins University School of Medicine Baltimore, MD, USA, James Robert Brašić, The Russell H. Morgan Department of Radiology and Radiological Science The Johns Hopkins University School of Medicine Baltimore, MD, USA, Nicola Cascella, Department of Psychiatry and Behavioral Sciences The Johns Hopkins University School of Medicine Baltimore, MD, USA
  • Edited by Martha E. Shenton, Bruce I. Turetsky, University of Pennsylvania
  • Book: Understanding Neuropsychiatric Disorders
  • Online publication: 10 January 2011
  • Chapter DOI: https://doi.org/10.1017/CBO9780511782091.005
Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

  • Neuroreceptor imaging of schizophrenia
    • By Dean F. Wong, The Russel H. Morgan Department of Radiology and Radiological Science The Johns Hopkins University School of Medicine Baltimore, MD, USA, James Robert Brašić, The Russell H. Morgan Department of Radiology and Radiological Science The Johns Hopkins University School of Medicine Baltimore, MD, USA, Nicola Cascella, Department of Psychiatry and Behavioral Sciences The Johns Hopkins University School of Medicine Baltimore, MD, USA
  • Edited by Martha E. Shenton, Bruce I. Turetsky, University of Pennsylvania
  • Book: Understanding Neuropsychiatric Disorders
  • Online publication: 10 January 2011
  • Chapter DOI: https://doi.org/10.1017/CBO9780511782091.005
Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

  • Neuroreceptor imaging of schizophrenia
    • By Dean F. Wong, The Russel H. Morgan Department of Radiology and Radiological Science The Johns Hopkins University School of Medicine Baltimore, MD, USA, James Robert Brašić, The Russell H. Morgan Department of Radiology and Radiological Science The Johns Hopkins University School of Medicine Baltimore, MD, USA, Nicola Cascella, Department of Psychiatry and Behavioral Sciences The Johns Hopkins University School of Medicine Baltimore, MD, USA
  • Edited by Martha E. Shenton, Bruce I. Turetsky, University of Pennsylvania
  • Book: Understanding Neuropsychiatric Disorders
  • Online publication: 10 January 2011
  • Chapter DOI: https://doi.org/10.1017/CBO9780511782091.005
Available formats
×